JP2019515003A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515003A5 JP2019515003A5 JP2018559369A JP2018559369A JP2019515003A5 JP 2019515003 A5 JP2019515003 A5 JP 2019515003A5 JP 2018559369 A JP2018559369 A JP 2018559369A JP 2018559369 A JP2018559369 A JP 2018559369A JP 2019515003 A5 JP2019515003 A5 JP 2019515003A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituents
- halo
- alkoxy
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- -1 tetrahydronaphthalinyl Chemical group 0.000 claims description 62
- 125000001475 halogen functional group Chemical group 0.000 claims description 42
- 150000001875 compounds Chemical class 0.000 claims description 40
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 125000001188 haloalkyl group Chemical group 0.000 claims description 30
- 125000001424 substituent group Chemical group 0.000 claims description 26
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 23
- 239000003112 inhibitor Substances 0.000 claims description 20
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 12
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000003386 piperidinyl group Chemical group 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- 125000000335 thiazolyl group Chemical group 0.000 claims description 12
- 125000003342 alkenyl group Chemical group 0.000 claims description 11
- 208000031886 HIV Infections Diseases 0.000 claims description 8
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 claims description 8
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 8
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 8
- 239000002777 nucleoside Substances 0.000 claims description 8
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 8
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 8
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000037357 HIV infectious disease Diseases 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 6
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims description 6
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 6
- 125000001041 indolyl group Chemical group 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 125000002757 morpholinyl group Chemical group 0.000 claims description 6
- 125000004193 piperazinyl group Chemical group 0.000 claims description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims description 4
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 claims description 4
- 229940122440 HIV protease inhibitor Drugs 0.000 claims description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 claims description 4
- 230000034303 cell budding Effects 0.000 claims description 4
- RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 4
- 229960002542 dolutegravir Drugs 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000002835 hiv fusion inhibitor Substances 0.000 claims description 4
- 239000004030 hiv protease inhibitor Substances 0.000 claims description 4
- 230000035800 maturation Effects 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662334718P | 2016-05-11 | 2016-05-11 | |
| US62/334,718 | 2016-05-11 | ||
| PCT/IB2017/052701 WO2017195113A1 (en) | 2016-05-11 | 2017-05-09 | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515003A JP2019515003A (ja) | 2019-06-06 |
| JP2019515003A5 true JP2019515003A5 (enExample) | 2020-04-23 |
Family
ID=58745295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559369A Pending JP2019515003A (ja) | 2016-05-11 | 2017-05-09 | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10407410B2 (enExample) |
| EP (1) | EP3455215A1 (enExample) |
| JP (1) | JP2019515003A (enExample) |
| WO (1) | WO2017195113A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3455217A1 (en) * | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| US20200016136A1 (en) * | 2017-01-03 | 2020-01-16 | Viiv Healthcare Uk (No. 5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TW201835068A (zh) * | 2017-01-03 | 2018-10-01 | 英商Viiv醫療保健英國(No.5)有限公司 | 作為人類免疫缺乏病毒複製之抑制劑之吡啶-3-基乙酸衍生物 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7939545B2 (en) | 2006-05-16 | 2011-05-10 | Boehringer Ingelheim International Gmbh | Inhibitors of human immunodeficiency virus replication |
| SI2220076T1 (sl) | 2007-11-15 | 2012-05-31 | Gilead Sciences Inc | Inhibitorji replikacije virusa humane imunske pomankljivosti |
| KR20100108337A (ko) | 2007-11-15 | 2010-10-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 사람 면역결핍 바이러스 복제의 억제제 |
| JP5269087B2 (ja) | 2007-11-16 | 2013-08-21 | ギリアード サイエンシス インコーポレーテッド | ヒト免疫不全ウイルス複製のインヒビター |
| US8354429B2 (en) | 2007-11-16 | 2013-01-15 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US8338441B2 (en) * | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| GB0908394D0 (en) | 2009-05-15 | 2009-06-24 | Univ Leuven Kath | Novel viral replication inhibitors |
| GB0913636D0 (en) | 2009-08-05 | 2009-09-16 | Univ Leuven Kath | Novel viral replication inhibitors |
| WO2011076765A1 (en) | 2009-12-23 | 2011-06-30 | Katholieke Universiteit Leuven | Novel antiviral compounds |
| US8633200B2 (en) | 2010-09-08 | 2014-01-21 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US8629276B2 (en) | 2012-02-15 | 2014-01-14 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| US9034882B2 (en) | 2012-03-05 | 2015-05-19 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| JP2016512511A (ja) | 2013-03-13 | 2016-04-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ヒト免疫不全ウイルス複製の阻害剤 |
| WO2014159959A1 (en) | 2013-03-14 | 2014-10-02 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| CA2939656C (en) * | 2014-02-18 | 2017-07-11 | Transocean Sedco Forex Ventures Limited | Method and apparatus for subsea hose replacement |
| US9193720B2 (en) * | 2014-02-20 | 2015-11-24 | Bristol-Myers Squibb Company | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| TWI657086B (zh) * | 2015-08-11 | 2019-04-21 | 英商Viiv醫療保健英國(No.5)有限公司 | 做為人類免疫缺陷病毒複製抑制劑之５－（ｎ－苯甲基四氫異喹啉－６－基）吡啶－３－基乙酸衍生物 |
| BR112018003181A2 (pt) * | 2015-08-20 | 2018-09-25 | Viiv Healthcare Uk No 5 Ltd | composto, composição, e, método para tratar infecção por hiv |
| EP3455217A1 (en) * | 2016-05-11 | 2019-03-20 | ViiV Healthcare UK (No.5) Limited | Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication |
| JP2019515939A (ja) * | 2016-05-11 | 2019-06-13 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤としてのピリジン−３−イル酢酸誘導体 |
-
2017
- 2017-05-09 US US16/094,536 patent/US10407410B2/en not_active Expired - Fee Related
- 2017-05-09 EP EP17724921.6A patent/EP3455215A1/en not_active Withdrawn
- 2017-05-09 WO PCT/IB2017/052701 patent/WO2017195113A1/en not_active Ceased
- 2017-05-09 JP JP2018559369A patent/JP2019515003A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020085493A5 (enExample) | ||
| JP2017526748A5 (enExample) | ||
| JP2016512507A5 (enExample) | ||
| JP2016512511A5 (enExample) | ||
| JP2018522927A5 (enExample) | ||
| JP2018524390A5 (enExample) | ||
| JP2016528301A5 (enExample) | ||
| MX2024001849A (es) | Antagonista del receptor del factor de liberacion de corticotropina 1 (crf1), formulaciones farmaceuticas y formas solidas del mismo para el tratamiento de hiperplasia suprarrenal congenita. | |
| RU2017127135A (ru) | Терапевтическое средство против рака желчных протоков | |
| MX2015012760A (es) | Composicion farmaceutica que comprende un activador de ampk y un agente serotonergico y metodos de uso de la misma. | |
| JP2017504611A5 (enExample) | ||
| JP2015524841A5 (enExample) | ||
| JP2016535795A5 (enExample) | ||
| RU2017107715A (ru) | Производные имидазо[1,2-a]пиридина для применения в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2007519649A5 (enExample) | ||
| RU2018106498A (ru) | Производные 5-(N-конденсированный трициклический арил-тетрагидроизохинолин-6-ил) пиридин-3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| JP2017504631A5 (enExample) | ||
| JP2018522045A5 (enExample) | ||
| JP2016530213A5 (enExample) | ||
| RU2018106504A (ru) | Производные пиридин 3-ил-уксусной кислоты в качестве ингибиторов репликации вируса иммунодефицита человека | |
| RU2017145649A (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ НА ОСНОВЕ АНТИТЕЛА К CD20 В СОЧЕТАНИИ С ИНГИБИТОРОМ BeI-2 И ИНГИБИТОРОМ MDM2 | |
| IL257240A (en) | History of 5– (n– benzyl tetrahydroisoquinoline – 6 – il) Pyridine – 3 – il Acetic acid as inhibitors of human immunodeficiency virus replication | |
| GEAP202215588A (en) | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors | |
| GEAP202215599A (en) | Boron containing pde4 inhibitors | |
| RU2016142611A (ru) | Пролекарственные средства ингибиторов обратной транскриптазы вич |